机构名称：
¥ 2.0
最初的应用 - ANCA相关的血管炎的应用来自任何相关从业者。批准有效期为8周。先决条件（在适当的情况下）□患者已被诊断出患有ANCA相关的血管炎*和□□总的利妥昔单抗剂量不会超过每周的375 mg/m 2的体面面积的375 mg/m 2，总共4周，□以前有大量疾病或诱导率均可在每天或脉搏静脉注射术中，至少有大量疾病的疾病，至少有脉搏静脉注射效果。 cumulative dose of cyclophosphamide > 15 g or a further repeat 3 month induction course of cyclophosphamide would result in a cumulative dose > 15 g or □ Cyclophosphamide and methotrexate are contraindicated or □ Patient is a female of child-bearing potential or □ Patient has a previous history of haemorrhagic cystitis, urological malignancy or haematological malignancy
特殊当局-Rituximab（Riximyo）
主要关键词
相关文件推荐
